Johnson & Johnson (J&J) has announced its intention to invest more than $55 billion in the United States over the next four years.

This initiative entails the development of four new manufacturing plants, signifying a 25% rise in the company's U.S. investments compared to the last four years.

The first of these facilities will be situated in Wilson, North Carolina, with an investment surpassing $2 billion.

This plant is projected to generate around 5,000 construction jobs and more than 500 permanent positions upon its completion.

The new facilities will concentrate on manufacturing advanced medications for cancer, immune-mediated disorders, and neurological conditions.

This strategic initiative is in line with the company's goal of enhancing its U.S. manufacturing capacities.

The announcement is set against the backdrop of proposed 25% tariffs on imported pharmaceuticals by the Trump administration, aimed at promoting domestic manufacturing.

J&J's expansion strategy mirrors similar pledges from other large corporations, indicating a wider movement towards reshoring manufacturing to the United States.